Cargando…

The Value of Anlotinib in the Treatment of Intractable Brain Edema: Two Case Reports

About 20-30 percent of patients with cancer, such as non-small cell lung cancer, breast cancer, melanoma and renal cell carcinoma, will develop brain metastases (BM). Primary and secondary brain tumors are often accompanied by peritumoral edema. Due to the limited intracranial space, peritumoral ede...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Song, Sun, Jian, Xu, Mingna, Wang, Yuru, Liu, Guihong, Jiang, Aijun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020902/ https://www.ncbi.nlm.nih.gov/pubmed/33828975 http://dx.doi.org/10.3389/fonc.2021.617803

Ejemplares similares

Efficacy of Anlotinib for the Treatment of Angiosarcoma of the Face and Neck: A Case Report
por: Ren, Biyong, et al.
Publicado: (2021)

Anlotinib for the Treatment of Multiple Recurrent Lumbar and Sacral Cord Hemangioblastomas: A Case Report
por: Jin, Nan, et al.
Publicado: (2022)

Successful treatment using apatinib in intractable brain edema: A case report and literatures review
por: Song, Yanqiu, et al.
Publicado: (2018)

Malignant mediastinal mesothelioma treated with anlotinib: a case report and review of the literature
por: Zhang, Yishi, et al.
Publicado: (2023)

Combination of Anlotinib and Celecoxib for the Treatment of Abdominal Desmoid Tumor: A Case Report and Literature Review
por: Wang, Jianzheng, et al.
Publicado: (2022)

Anlotinib combined with whole-brain radiotherapy in non-small cell lung cancer with multiple brain metastases that progressed or developed after at least one lines of prior treatment
por: Kong, Cheng, et al.
Publicado: (2023)

Case report: Unique FLT4 variants associated with differential response to anlotinib in angiosarcoma
por: Gu, Yuanyuan, et al.
Publicado: (2022)

Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation
por: Cao, Jian-zhou, et al.
Publicado: (2021)

Association between anlotinib trough plasma concentration and treatment outcomes in advanced non-small-cell lung cancer
por: Chen, Ling, et al.
Publicado: (2023)

Case Report: PD-L1-negative advanced bladder cancer effectively treated with anlotinib and tislelizumab: A report of two cases
por: Li, Teng, et al.
Publicado: (2023)

Long-term survival with anlotinib as a front-line treatment in an elderly NSCLC patient: A case report
por: Wang, Jingyi, et al.
Publicado: (2023)

Efficacy and safety of anlotinib plus programmed death-1 blockade versus anlotinib monotherapy as second or further-line treatment in advanced esophageal squamous cell carcinoma: A retrospective study
por: Liu, Ying, et al.
Publicado: (2022)

The efficacy and adverse effects of anlotinib in the treatment of high-grade glioma: A retrospective analysis
por: Shen, Fangcheng, et al.
Publicado: (2023)

Novel Nanocrystal Injection of Insoluble Drug Anlotinib and Its Antitumor Effects on Hepatocellular Carcinoma
por: Luo, Mei, et al.
Publicado: (2021)

Efficacy and safety of anlotinib-based treatment in metastatic breast cancer patients
por: Qian, Yu, et al.
Publicado: (2022)

Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab
por: Liu, Zhujun, et al.
Publicado: (2022)

Anlotinib combined with TAS-102 as the third-line treatment for a patient with metastatic colon cancer: A case report
por: Li, Qizheng, et al.
Publicado: (2022)

A Short-Term Efficacy of Anlotinib in the Treatment of Refractory Nasopharyngeal Inverted Papilloma: A Case Report
por: Yang, Pan, et al.
Publicado: (2021)

Anlotinib-induced acute myocardial infarction: A case report and literature review
por: Liu, Guihong, et al.
Publicado: (2020)

Tocilizumab (monoclonal anti-IL-6R antibody) reverses anlotinib resistance in osteosarcoma
por: Xu, Jiuhui, et al.
Publicado: (2023)

A Retrospective Analysis of the Effect of Anlotinib in Patients With Lung Cancer With or Without Previous Antiangiogenic Therapy
por: Suo, Jiaojiao, et al.
Publicado: (2021)

Anlotinib Combined With Chemotherapy for Recurrence of Pulmonary Sarcomatoid Cancer Previously Surgically Treated: A Case Report and Literature Review
por: Li, Jing, et al.
Publicado: (2021)

Treatment of intractable epistaxis in patients with nasopharyngeal cancer
por: Yang, Xiaojing, et al.
Publicado: (2023)

Successful Treatment of an Elderly Patient With Combined Small Cell Lung Cancer Receiving Anlotinib: A Case Report
por: Gan, Yuying, et al.
Publicado: (2021)

Case Report: Advanced pulmonary sarcomatoid carcinoma with adrenal gland metastasis after sintilimab combined with anlotinib treatment
por: Dai, Gangyi, et al.
Publicado: (2023)

Application of Anlotinib Combined With Neoadjuvant Chemotherapy in Primary EWS/PNET of Lung: A Case Report
por: Fan, YH, et al.
Publicado: (2022)

Basket Trials for Intractable Cancer
por: Qin, Bao-Dong, et al.
Publicado: (2019)

Anlotinib combined with pembrolizumab as first-line treatment for advanced pulmonary sarcomatoid carcinoma: a case report and literature review
por: Wen, Yingmei, et al.
Publicado: (2023)

Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma
por: Li, Shenglong
Publicado: (2021)

Longitudinal Pharmacometabonomics for Predicting Malignant Tumor Patient Responses to Anlotinib Therapy: Phenotype, Efficacy, and Toxicity
por: Hu, Ting, et al.
Publicado: (2020)

Adjuvant single-fraction radiotherapy is safe and effective for intractable keloids
por: Song, Changhoon, et al.
Publicado: (2014)

Case Report: Long-Term Survival With Anlotinib in a Patient With Advanced Undifferentiated Large-Cell Lung Cancer and Rare Tonsillar Metastasis
por: Xu, Tianwei, et al.
Publicado: (2021)

Case Report: An Adolescent Soft Tissue Sarcoma With YWHAE-NUTM2B Fusion Is Effectively Treated With Combined Therapy of Epirubicin and Anlotinib
por: He, Jiajia, et al.
Publicado: (2022)

Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer
por: Xiong, Qi, et al.
Publicado: (2021)

Efficacy and Safety of Anlotinib in the Treatment of Small Cell Lung Cancer: A Real-World Observation Study
por: Yuan, Jing, et al.
Publicado: (2022)

Case Report: Toripalimab Combined With Anlotinib in a Patient With Metastatic Upper Tract Urothelial Carcinoma After Pembrolizumab Failure
por: Zan, Ning, et al.
Publicado: (2022)

Anlotinib Combined With Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma
por: Shi, Jingzhen, et al.
Publicado: (2020)

Outcomes of Anlotinib Maintenance Therapy in Patients With Advanced NSCLC in a Real-World Setting
por: Li, Jia, et al.
Publicado: (2022)

Case report: Significant benefits of tislelizumab combined with anlotinib in first-line treatment of metastatic renal pelvic urothelial carcinoma with sarcomatoid carcinoma differentiation
por: Zhu, Shibin, et al.
Publicado: (2022)

A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer
por: Huang, Jia-Yi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dhs02s3u2kag6h3j6kpj96r6fi